[go: up one dir, main page]

MX2018015892A - Derivados de acido boronico y usos terapeuticos de los mismos. - Google Patents

Derivados de acido boronico y usos terapeuticos de los mismos.

Info

Publication number
MX2018015892A
MX2018015892A MX2018015892A MX2018015892A MX2018015892A MX 2018015892 A MX2018015892 A MX 2018015892A MX 2018015892 A MX2018015892 A MX 2018015892A MX 2018015892 A MX2018015892 A MX 2018015892A MX 2018015892 A MX2018015892 A MX 2018015892A
Authority
MX
Mexico
Prior art keywords
acid derivatives
boronic acid
therapeutic uses
compositions
bli
Prior art date
Application number
MX2018015892A
Other languages
English (en)
Other versions
MX389349B (es
Inventor
Rodny Olga
Glinka Tomasz
Hecker Scott
K Reddy Raja
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of MX2018015892A publication Critical patent/MX2018015892A/es
Publication of MX389349B publication Critical patent/MX389349B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen compuestos antimicrobianos, composiciones, composiciones farmacéuticas, el método de uso y preparación de los mismos. Algunas modalidades se refieren a derivados de ácido borónico y su uso como agentes terapéuticos, por ejemplo, inhibidores de ß-lactamasa (BLI).
MX2018015892A 2016-06-30 2017-06-28 Derivados de ácido borónico y usos terapéuticos de los mismos. MX389349B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357165P 2016-06-30 2016-06-30
PCT/US2017/039787 WO2018005662A1 (en) 2016-06-30 2017-06-28 Boronic acid derivatives and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
MX2018015892A true MX2018015892A (es) 2019-06-20
MX389349B MX389349B (es) 2025-03-20

Family

ID=60785544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015892A MX389349B (es) 2016-06-30 2017-06-28 Derivados de ácido borónico y usos terapéuticos de los mismos.

Country Status (23)

Country Link
US (5) US10294249B2 (es)
EP (1) EP3478693B1 (es)
JP (1) JP7060245B2 (es)
KR (1) KR102403296B1 (es)
CN (1) CN109415386B (es)
AU (1) AU2017290060B2 (es)
BR (1) BR112018077015B1 (es)
CA (1) CA3026582A1 (es)
CL (1) CL2018003681A1 (es)
CO (1) CO2018013978A2 (es)
DK (1) DK3478693T3 (es)
ES (1) ES2894251T3 (es)
IL (1) IL263450B (es)
MX (1) MX389349B (es)
MY (1) MY196909A (es)
PH (1) PH12018502747A1 (es)
PL (1) PL3478693T3 (es)
PT (1) PT3478693T (es)
SA (1) SA518400742B1 (es)
SG (1) SG11201811549UA (es)
UA (1) UA124464C2 (es)
WO (1) WO2018005662A1 (es)
ZA (1) ZA201808327B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
PL3592362T3 (pl) 2017-03-06 2025-06-23 VenatoRx Pharmaceuticals, Inc. Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3694864B1 (en) * 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019204419A1 (en) * 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
MA54319A (fr) * 2018-11-29 2021-10-06 Venatorx Pharmaceuticals Inc Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EP3986419B1 (en) 2019-06-19 2025-05-14 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
TW202123945A (zh) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 具有抗菌作用的醫藥組成物
CA3155559A1 (en) * 2019-10-25 2021-04-29 Sachiko Koike Novel substituted condensed ring compound
EP4121433A4 (en) * 2020-03-18 2024-06-19 Qpex Biopharma, Inc. BORIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
MX2022013890A (es) * 2020-05-05 2022-11-30 Qpex Biopharma Inc Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
CN116615431A (zh) * 2020-08-20 2023-08-18 辉诺生物医药科技（杭州）有限公司 硼酸类化合物
WO2022217199A1 (en) * 2021-04-05 2022-10-13 Qpex Biopharma, Inc. Ceftibuten dosing regimens
TW202302119A (zh) 2021-04-13 2023-01-16 大陸商上海拓界生物醫藥科技有限公司 作為β－內醯胺酶抑制劑的硼酸衍生物
CN113150022B (zh) * 2021-04-23 2022-12-06 四川大学 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途
CA3235292A1 (en) * 2021-10-19 2023-04-27 Jianmin Zhang Tricyclic boronic acid derivative, and preparation method therefor and application thereof
CN119384424A (zh) * 2022-02-18 2025-01-28 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
CN114716465B (zh) * 2022-05-06 2024-05-24 上海中医药大学 一种双环硼酸酯类化合物的制备方法及其应用
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) * 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CA1283404C (en) 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6075014A (en) 1997-06-13 2000-06-13 Northwestern University Inhibitors of β-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
PT1216239E (pt) 1999-09-25 2004-05-31 Smithkline Beecham Plc Derivados de piperazina como antagonistas de 5-ht1b
AU762935B2 (en) 1999-10-28 2003-07-10 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (en) 2000-09-12 2002-03-21 Shoichet Brian K β-LACTAM ANALOGS AND USES THEREFOR
BR0113861A (pt) 2000-09-14 2004-01-27 Pantherix Ltd Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
US6586615B1 (en) 2001-01-10 2003-07-01 Bristol-Myers Squibb Company α-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
EP2325225B2 (en) 2002-10-30 2019-12-11 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
MXPA05006798A (es) 2002-12-20 2006-03-09 Migenix Corp Ligandos de adenina nucleotido translocasa (ant) y composiciones y metodos relacionados a estos.
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
DE602004008098T8 (de) 2003-10-10 2008-04-17 Pfizer Products Inc., Groton Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren
WO2005047297A1 (en) * 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
KR101456815B1 (ko) 2005-02-16 2014-10-31 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
DK2484680T3 (da) 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
PL1988779T3 (pl) 2006-02-16 2015-10-30 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
KR101320718B1 (ko) 2007-03-23 2013-10-21 바실리어 파마슈티카 아게 세균 감염 치료용 조합 약제
EP2181103B1 (en) * 2007-07-23 2015-08-05 The Board Of Trustees Of The University Of Illinois System for controlling the reactivity of boronic acids
EA201070339A1 (ru) * 2007-09-06 2010-10-29 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
KR20100113485A (ko) 2007-11-13 2010-10-21 프로테즈 파마슈티칼스, 인크. 베타-락타마제 억제제
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
EP2406233B1 (en) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
AU2010259002B2 (en) 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
AU2010281439A1 (en) 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
EP2539348A4 (en) 2010-02-26 2013-07-24 Gary Igor Dmitrienko CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
JP5603487B2 (ja) 2010-06-10 2014-10-08 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド ヨウ化物の調製のためのプロセス
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102320960A (zh) 2011-08-02 2012-01-18 安徽东健化工科技有限公司 一种6-氟水杨酸的制备方法
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
EA201400735A1 (ru) 2011-12-22 2015-04-30 Арес Трейдинг С.А. Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EP2802593A1 (en) 2012-01-09 2014-11-19 The University of Tromsoe Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PT2928898T (pt) * 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2014227571B2 (en) 2013-03-15 2017-02-02 Intrexon Corporation Boron-containing diacylhydrazines
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2016016666A (es) 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016116892A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Antibacterial compositions
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2982911C (en) 2015-04-24 2023-10-03 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
KR20190039137A (ko) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 박테리아 감염 치료에서 사용하기 위한 세프티부텐과 클라불란산의 조합
CN106397455B (zh) 2016-08-30 2018-08-31 山东罗欣药业集团恒欣药业有限公司 一种抗感染药物头孢布烯晶体化合物及其组合物
CN106397454B (zh) 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
AU2017325863B2 (en) 2016-09-16 2021-08-19 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
CN106432270A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432272A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106397457A (zh) 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106420617A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯粉针剂
CN106420760A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯组合物
CN106432271A (zh) 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
TW201925201A (zh) 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
CN109293678A (zh) 2018-11-20 2019-02-01 湖北凌晟药业有限公司 一种头孢布烯的制备方法
MA54319A (fr) 2018-11-29 2021-10-06 Venatorx Pharmaceuticals Inc Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EP3986419B1 (en) 2019-06-19 2025-05-14 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US20210060033A1 (en) 2019-08-29 2021-03-04 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections
EP4121433A4 (en) 2020-03-18 2024-06-19 Qpex Biopharma, Inc. BORIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
MX2022013890A (es) 2020-05-05 2022-11-30 Qpex Biopharma Inc Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
WO2022217199A1 (en) 2021-04-05 2022-10-13 Qpex Biopharma, Inc. Ceftibuten dosing regimens
EP4362950A4 (en) 2021-07-01 2025-08-13 Qpex Biopharma Inc CRYSTALLINE FORMS OF CEFTIBUTEN

Also Published As

Publication number Publication date
JP2019527196A (ja) 2019-09-26
US11999759B2 (en) 2024-06-04
RU2018143900A3 (es) 2020-09-29
MY196909A (en) 2023-05-09
US20200181177A1 (en) 2020-06-11
ES2894251T3 (es) 2022-02-14
EP3478693B1 (en) 2021-07-21
JP7060245B2 (ja) 2022-04-26
SA518400742B1 (ar) 2023-02-28
CL2018003681A1 (es) 2019-04-26
US20180002351A1 (en) 2018-01-04
MX389349B (es) 2025-03-20
BR112018077015A2 (pt) 2019-04-02
US10570159B2 (en) 2020-02-25
AU2017290060B2 (en) 2021-07-22
US12509475B2 (en) 2025-12-30
EP3478693A4 (en) 2020-02-19
SG11201811549UA (en) 2019-01-30
UA124464C2 (uk) 2021-09-22
NZ749864A (en) 2025-06-27
US20190233443A1 (en) 2019-08-01
PL3478693T3 (pl) 2021-12-13
DK3478693T3 (da) 2021-09-20
CN109415386A (zh) 2019-03-01
CA3026582A1 (en) 2018-01-04
AU2017290060A1 (en) 2018-12-20
US20250034175A1 (en) 2025-01-30
CO2018013978A2 (es) 2019-02-08
US20220056055A1 (en) 2022-02-24
EP3478693A1 (en) 2019-05-08
PT3478693T (pt) 2021-10-25
BR112018077015B1 (pt) 2022-05-03
WO2018005662A1 (en) 2018-01-04
RU2018143900A (ru) 2020-07-30
IL263450B (en) 2022-01-01
KR20190025953A (ko) 2019-03-12
ZA201808327B (en) 2022-04-28
PH12018502747A1 (en) 2019-12-11
US11180512B2 (en) 2021-11-23
KR102403296B1 (ko) 2022-05-27
US10294249B2 (en) 2019-05-21
CN109415386B (zh) 2022-04-19
IL263450A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CL2017002650A1 (es) Compuestos novedosos
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY35467A (es) Compuestos orgánicos
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
CR20170003A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX2018013701A (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.